Home Cart Sign in  
Chemical Structure| 358721-70-7 Chemical Structure| 358721-70-7

Structure of UBCS039
CAS No.: 358721-70-7

Chemical Structure| 358721-70-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

UBCS039 is a specific Sirtuin 6 activator which showed robust activating effects on Sirt6-dependent H3K18ac deacetylation of both full-length histone proteins and complete HeLa nucleosomes.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

DE Stock

US Stock

Asia Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of UBCS039

CAS No. :358721-70-7
Formula : C16H13N3
M.W : 247.29
SMILES Code : C1(NC2=CC=CC=C2N3C=CC=C13)C4=CN=CC=C4
MDL No. :MFCD00206184
InChI Key :BSOBGTYXYGHUTD-UHFFFAOYSA-N
Pubchem ID :2803797

Safety of UBCS039

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of UBCS039

epigenetics

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HeLa epithelial cervix carcinoma 75 µM UBCS039 induced deacetylation of histone H3K9 Cell Death Dis. 2018 Sep 24;9(10):996.
HCT116 colon carcinoma 75 µM UBCS039 induced deacetylation of histone H3K9 Cell Death Dis. 2018 Sep 24;9(10):996.
HT1080 human fibrosarcoma 75 µM UBCS039 triggered deacetylation of histone H3K56 Cell Death Dis. 2018 Sep 24;9(10):996.
H1299 non-small cell lung cancer 75 µM UBCS039 induced a time-dependent deacetylation of histone H3K9 Cell Death Dis. 2018 Sep 24;9(10):996.
BMDM cells 150 μM 24 h To investigate the effect of SIRT6 activation on M1/M2 phenotype shift in macrophages, the results showed that UBCS039 treatment could shift macrophages from M1 to M2 phenotype. Cell Biosci. 2021 Dec 14;11(1):210.
RAW264.7 cells 150 μM 24 h To investigate the effect of SIRT6 activation on M1/M2 phenotype shift in macrophages, the results showed that UBCS039 treatment could shift macrophages from M1 to M2 phenotype. Cell Biosci. 2021 Dec 14;11(1):210.
ZAS-stimulated podocytes 100 µM 4 h Treatment with UBCS039 preserved the expression of podocyte-specific proteins (podocin, nephrin, and podocalyxin) and significantly inhibited the protein expression of β-catenin and its downstream gene products, including Snail1 and Twist. Acta Pharmacol Sin. 2024 Jan;45(1):137-149.
mouse platelets 100 μM 30 min UBCS039 pretreatment significantly inhibited thrombin-induced platelet aggregation. Front Pharmacol. 2023 Dec 18;14:1268708.
H9c2 cells 100 μM 24 h UBCS039 reversed the inhibitory effect of D-galactose on cell proliferation and reduced the apoptosis rate. Aging (Albany NY). 2022 Dec 6;14(23):9730-9757.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.04mL

0.81mL

0.40mL

20.22mL

4.04mL

2.02mL

40.44mL

8.09mL

4.04mL

References

 

Historical Records

Categories